36.61 +0.05 (0.15%)
After hours: 4:26PM EST
|Bid||0.00 x 2200|
|Ask||0.00 x 1300|
|Day's Range||36.49 - 36.81|
|52 Week Range||31.01 - 39.45|
|Beta (3Y Monthly)||1.18|
|PE Ratio (TTM)||95.96|
|Earnings Date||Feb 4, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||40.29|
Fourth generation latent TB blood test provides flexible workflow and novel CD8 technology for a more complete picture of patients' immune response to tuberculosis infection
Hey Boston, Montgomery County wants your biotech talent. In an unprecedented move, the Montgomery County Economic Development Corp. is in the early stages of planning an office in the Boston-Cambridge area to recruit companies from the region's rich biotech and life sciences industry. Bob Buchanan, a local developer who chairs the Montgomery County Economic Development Corp., told me Wednesday afternoon the corporation will hire real estate company JLL (NYSE: JLL) to conduct a life sciences market analysis, identify recruitment opportunities and propose potential locations for the office.
This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios). To keep it practical, we'll show how QIAGEN N.V.'s (NYSE:QGEN) P/E Read More...
# Qiagen NV ### NYSE:QGEN View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is low for QGEN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, growth of ETFs holding QGEN is favorable, with net inflows of $15.01 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to email@example.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
QIAGEN (QGEN) pins high hopes on its strategic tie-ups with Hamilton and DiaSorin. It unveils a CE-marked DiaSorin automation solution in Europe to use the LIAISON system for test read-out.
Adapting the power of QuantiFERON®-TB technology to advance global TB control efforts in new partnership with Ellume
Enhancing QIAGEN’s industry-leading position with access to MarkerMine™ database and real-world evidence insights that provide insights for targeted therapy options
Preparing for 2020 launch of novel digital PCR systems with fully integrated workflow and menu of QIAGEN assays, advantages of improved multiplexing, throughput and scalability
Enabling labs to efficiently process increasingly complex samples with over 3,000 proven protocols, advanced digital capabilities and connectivity
QIAGEN N.V. announces that it will initiate the repurchase of a third tranche of shares under the share repurchase program which was announced by an ad hoc announcement dated January 31, 2018. In the time period between December 19, 2018 until March 8, 2019, at the latest, a third tranche of up to 2.5 million common shares of the Company having a total purchase price of up to USD 70 million (or the equivalent Euro amount thereof, in each case without ancillary purchasing costs) shall be repurchased exclusively on the electronic trading platform of the Frankfurt Stock Exchange (XETRA). The maximum purchase price per share (excluding ancillary purchase costs) will not exceed the average closing price for the last five trading days prior to the day of purchase on the electronic trading platform of the Frankfurt Stock Exchange by more than 10%.
Does Qiagen NV (NYSE:QGEN) represent a good buying opportunity at the moment? Let’s briefly check the hedge fund interest towards the company. Hedge fund firms constantly search out bright intellectuals and highly-experienced employees and throw away millions of dollars on research activities, so it is no wonder why they tend to generate millions in profits […]
When QIAGEN NV (NYSE:QGEN) announced its most recent earnings (30 September 2018), I compared it against two factor: its historical earnings track record, and the performance of its industry peers Read More...
Fast-tracking clinical readiness of test to support identification of patients eligible for novel Novartis PI3K inhibitor BYL719
The tie-up with NeoGenomics is expected to enable QIAGEN (QGEN) and pharmaceutical partners streamline the development and introduction of targeted drugs and companion diagnostics.
Partners discuss efforts to accelerate precision medicine solutions at ASH 2018 HILDEN, Germany and GERMANTOWN, Md. and FORT MYERS, Fla., Nov. 30, 2018 -- QIAGEN N.V. (NYSE:.
Partners discuss efforts to accelerate precision medicine solutions at ASH 2018
Highlighting Sample to Insight solutions for next-generation sequencing at American Society of Hematology 2018 meeting
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NEW YORK, Nov. 13, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Read More...
The Vanguard Health Care Fund (Trades, Portfolio) released its third-quarter portfolio last week, listing four new positions. Warning! GuruFocus has detected 1 Warning Sign with ELAN. Managed by Jean Hynes, the fund invests in a number of diverse health care-related stocks from around the world in order to achieve long-term capital appreciation.